R3tatrutide

Description

What Is R3tatrutide?

R3ta is a synthetic investigational pep developed as a triple‑agonist targeting three key metabolic receptors: GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and glucagon receptors. This triple agonist design represents a new generation of incretin‑based therapies, aiming to provide superior metabolic benefits compared to single or dual agonists.

Mechanism of Action

R3ta simultaneously activates GLP‑1, GIP, and glucagon receptors. GLP‑1 receptor stimulation enhances insulin secretion, reduces appetite, and slows gastric emptying. GIP receptor activation supports insulin release and may improve adipose tissue metabolism. Glucagon receptor engagement increases energy expenditure and promotes lipid mobilization. Together, these pathways synergistically drive weight reduction, improve glycemic control, and enhance metabolic flexibility.

Research & Clinical Data

Phase 2 clinical trials have demonstrated R3ta’s remarkable efficacy in obesity management, with participants achieving substantial weight loss compared to existing GLP‑1 agonists. It has also shown improvements in HbA1c and fasting glucose in type 2 diabetes patients. Early data suggest potential benefits in non‑alcoholic fatty liver disease (NAFLD) and cardiometabolic risk reduction. Side effects are similar to other incretin therapies, including gastrointestinal symptoms such as nausea and vomiting. Regulatory approval is pending, with ongoing Phase 3 trials expected to clarify its therapeutic role.

Purity & Quality

Pharmaceutical‑grade investigational peptide. Certificate of Analysis available per batch. Regulatory status: investigational, not yet FDA or EMA‑approved.

Classification & Handling Class: Synthetic pep | Target: GLP‑1, GIP, glucagon receptors | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, pending approval